STE up +1.30% percent right now. $STE High is at 64.68 and

New Post Public Reply Private Reply Replies (0) Message Board
Lucky Jimmy
STE up +1.30% percent right now. $STE High is at 64.68 and the Low 63.55 with current volume of 197,889.

Recent News posted below.

STE Steris Corp Recent Headline News

Today's Strong And Under The Radar Stock Is Steris (STE)
at The Street - Tue Nov 11, 9:30AM CST
Trade-Ideas LLC identified Steris (STE) as a strong and under the radar candidate
STE: 64.21 (+0.57)

Steris Gains on Q2 Earnings and Revenue Beat; EPS View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 9:10AM CST
Following the earnings release, Steris' (STE) share price rose 1.9% to eventually close at $63.64 yesterday.
ABC: 88.04 (+0.33), BCR: 163.87 (unch), BRLI: 28.58 (-0.22), STE: 64.21 (+0.57)

STERIS Has Returned 37.2% Since SmarTrend Recommendation (STE)
Comtex SmarTrend(R) - Mon Nov 10, 9:23AM CST
SmarTrend identified an Uptrend for STERIS (NYSE:STE) on February 18th, 2014 at $45.55. In approximately 9 months, STERIS has returned 37.24% as of today's recent price of $62.51.
STE: 64.21 (+0.57)

Steris
at Investor's Business Daily - Wed Nov 05, 5:48PM CST
Steris (STE) earnings rose 23.6% to 68 cents, topping by a nickel. Revenue increased 20.6% to $462.7 mil, above views for $452.5 mil. The company set full-year EPS outlook for $2.86-$2.91 vs. views for $2.88 a share. Shares rose 0.4% to 62.66.
STE: 64.21 (+0.57)

STERIS' CEO Walter Rosebrough on Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 12:46PM CST

STE: 64.21 (+0.57)

Steris (STE) Q2 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 05, 8:55AM CST

STE: 64.21 (+0.57)

Steris beats by $0.05, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 2:21PM CST

STE: 64.21 (+0.57)

Stocks Turn Mixed; Epam Bounces Back
at Investor's Business Daily - Tue Nov 04, 2:13PM CST
Stocks continued to improve late Tuesday, turning mixed. The Dow Jones industrial average bounced back from a 0.5% loss and was up a fraction. The broader Nasdaq and the S&P 500 were off 0.4% each. They had been off 0.9% and 0.8%, respectively. NYSE...
FEYE: 32.98 (+0.59), AWAY: 30.76 (+1.10), FRGI: 55.77 (-0.74), SAVE: 78.71 (-0.34), LNKD: 229.54 (+0.29), SCTY: 50.24 (-1.54), STE: 64.21 (+0.57), PZZA: 49.84 (-0.57), JAZZ: 171.55 (-2.88), FL: 54.54 (-0.23), EPAM: 47.79 (+0.81)

Steris tops Street 2Q forecasts
Automated Insights - Tue Nov 04, 11:48AM CST
MENTOR, Ohio (AP) _ Steris Corp. (STE) on Tuesday reported earnings of $31 million in its fiscal second quarter.
STE: 64.21 (+0.57)

STERIS Corporation Announces Fiscal 2015 Second Quarter Results
Thomson Reuters ONE - Tue Nov 04, 10:30AM CST
- 21% Revenue Growth Fueled by Organic Growth and Acquisitions
STE: 64.21 (+0.57)

35.7% Return Seen to Date on SmarTrend STERIS Call (STE)
Comtex SmarTrend(R) - Fri Oct 31, 4:36PM CDT
SmarTrend identified an Uptrend for STERIS (NYSE:STE) on February 18th, 2014 at $45.55. In approximately 9 months, STERIS has returned 35.69% as of today's recent price of $61.80.
STE: 64.21 (+0.57)

DENTSPLY (XRAY) Beats Q3 Earnings, Misses on Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 3:30PM CDT
DENTSPLY International Inc. (XRAY) reported third-quarter 2014 adjusted earnings of 62 cents per share, which beat the Zacks Consensus Estimate by a couple of cents.
BRLI: 28.58 (-0.22), STE: 64.21 (+0.57), HSIC: 129.39 (-0.23), XRAY: 51.66 (+0.36)

STERIS Corporation to Announce Fiscal 2015 Second Quarter Financial Results on November 5, 2014
Thomson Reuters ONE - Tue Oct 28, 8:49AM CDT
Mentor, Ohio (October 28, 2014) - STERIS Corporation (NYSE: STE) today announced that it will release its fiscal 2015 second quarter financial results before the market opens on November 5, 2014, followed by a conference call at 10:00 a.m. Eastern Standard Time. The conference call can be heard live over the Internet at www.steris-ir.com or via phone by dialing 1- 800-369-8428 in the United States and Canada, or 1-773-799-3378 internationally, then referencing the password "STERIS".
STE: 64.21 (+0.57)

CONMED Q3 Earnings Rise but Revenues Fall - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 2:10PM CDT
CONMED Corporation (CNMD) reiterated its adjusted earnings and revenue guidance for full-year 2014.
STE: 64.21 (+0.57), CNMD: 42.26 (+0.17), COO: 159.70 (-0.72)

STERIS Shares Up 31.5% Since SmarTrend's Buy Recommendation (STE)
Comtex SmarTrend(R) - Fri Oct 24, 10:57AM CDT
SmarTrend identified an Uptrend for STERIS (NYSE:STE) on February 18th, 2014 at $45.55. In approximately 8 months, STERIS has returned 31.53% as of today's recent price of $59.90.
STE: 64.21 (+0.57)

NYSE stocks posting largest percentage increases
AP - Thu Oct 23, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on New York Stock Exchange at the close of trading:
CRS: 51.39 (-0.09), UFS: 40.57 (-0.38), CLV: 10.19 (-0.45), BBW: 18.39 (+0.39), CLF: 10.71 (-0.33), MTRN: 38.44 (+0.15), XRS: 32.17 (-0.81), GPI: 86.96 (+0.42), STE: 64.21 (+0.57), BRP: 23.50 (+0.16), TYL: 109.74 (-0.30), FUN: 47.01 (+0.30), UIS: 27.65 (+0.28), SIX: 40.18 (+0.25), TLLP: 56.84 (-0.72)

After Yesterday's Rally of 4.02% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Oct 22, 5:01PM CDT
STERIS (NYSE:STE) traded in a range yesterday that spanned from a low of $56.97 to a high of $59.21. Yesterday, the shares gained 4.0%, which took the trading range above the 3-day high of $56.87 on volume of 1.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
STE: 64.21 (+0.57)

Upgrade Alert for STERIS (STE)
Comtex SmarTrend(R) - Wed Oct 22, 6:55AM CDT
STERIS (NYSE:STE) was upgraded from Market Perform to Strong Buy at Raymond James today. The stock closed yesterday at $56.68 on volume of 484,000 shares, below average daily volume of 545,000. STERIS (NYSE:STE) has potential upside of 9.1% based on a current price of $56.68 and analysts' consensus price target of $61.83. The stock should find initial support at its 50-day moving average (MA) of $55.58 and further support at its 200-day MA of $51.36.
STE: 64.21 (+0.57)

Steris (STE) to Buy UK-based Synergy Health, Save Tax - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 2:30PM CDT
Following this news, Steris' (STE) share price inched up 0.3% immediately, but eventually dropped 2.5% to close at $54.99 yesterday.
STE: 64.21 (+0.57), CAH: 79.60 (+0.51), XRAY: 51.66 (+0.36), COO: 159.70 (-0.72)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Swanson Nexus Pro Launch: Boost for Dietitians

Updated Category News Views 184

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Continue Reading
Alaska's Insurance Maze: Coverage Over Cheap Policies

Updated Category News Views 138

Beyond Premiums: Assessing Real Coverage Needs The Alaskan wilderness isn't just home to stunning views; it's also a land where insurance needs to go beyond the average cookie-cutter policy. You'd think the cheapest option would suffice, but that's where residents might trip into financial quicksand. Devery Prince, a seasoned insurance principal, sheds light on why...

Continue Reading
Ping An's Bold Green Moves Ahead of APEC 2026

Updated Category News Views 0

Ping An's Pitch for Green: Talking the Talk and Walking the Walk? Well, here's something cooking in Shenzhen at the Ping An Finance Center—an international seminar championing green development initiatives. It's all buzz around Ping An Insurance (HKEX: 2318; SSE: 601318) flexing its green muscle, orchestrating conversations right before APEC 2026. Talk about timing....

Continue Reading
Likang's Bold Move: Cancer Immunotherapy at AD Summit

Updated Category News Views 134

Cancer Care Takes Center Stage Kicking off with a bang in Abu Dhabi, Likang Life Sciences has made a splash in the world of personalized cancer immunotherapy. The Abu Dhabi Future Health Summit 2026 served as the backdrop for this bold move, lighting up discussions with their AI-enabled innovations. Likang's showing at the Summit wasn't just another walk in the park—it...

Continue Reading
Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 197

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Updated Category News Views 204

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

Continue Reading
Apalutamide Boosts Outlook for Prostate Cancer Treatment

Updated Category News Views 69

Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 173

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
World Young Scientist Summit 2026 in Wenzhou Kicks Off

Updated Category News Views 154

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Continue Reading
Bio-Thera's New Data: A Game Changer for NSCLC?

Updated Category News Views 337

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...

Continue Reading

Top 5 Most Recently Viewed Articles

BerGenBio Welcomes First Patient in Lung Cancer Study

Updated Category News Views 202

BerGenBio Embarks on Promising Lung Cancer Trial BerGenBio ASA, a clinical-stage biopharmaceutical company dedicated to combating serious diseases through innovative therapies, has reached a significant milestone in its journey. The company has successfully included the first patient in its clinical trial, focusing on the cutting-edge AXL kinase inhibitor known as...

Continue Reading
CIMG Inc. Introduces Tokenized Stock on FlowStocks Platform

Updated Category News Views 247

CIMG Inc. Introduces Tokenized Stock on FlowStocks Platform CIMG Inc. (NASDAQ: IMG), a dynamic group in the digital health and sales development sector, has officially launched its tokenized stock on the FlowStocks platform. This exciting development follows successful testing and represents a significant shift in how the company interacts with its investors. The new...

Continue Reading
Exploring the Impact of New SEC Leadership on Cryptocurrency

Updated Category News Views 179

New Era for Cryptocurrency Under SEC Leadership The recent changes at the Securities and Exchange Commission (SEC) under new leadership signal a transformative period for the cryptocurrency market. These developments could reshape the regulatory landscape, offering clarity and direction for investors and companies involved in the digital asset space. Understanding the...

Continue Reading
Shytoshi Kusama Transitions Roles: Shiba Inu's New Direction

Updated Category News Views 190

Shytoshi Kusama Transitions to New Leadership Role Shytoshi Kusama, the driving force behind the Shiba Inu ecosystem, has made a significant change by stepping down from his role as the lead visionary. This pivotal shift marks a transition to the position of lead ambassador, as he aims to spearhead global adoption more effectively. The Shift in Leadership Announcing his...

Continue Reading
BASF Shares Fall Following Proposed Dividend Cuts to Shareholders

Updated Category News Views 281

BASF (ETR:BASFN) just took a hit on its stock price after announcing some major shifts in its dividend policy. Shares plummeted by 2.9% to €44.035, all thanks to the company's new proposed minimum annual dividend of €2.25 per share for the upcoming 2024 business year. That’s a stark drop from the previous €3.40 per share they dished out in 2023—talk about making...

Continue Reading